Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer

Table 1 Characteristics of the patients n (%)

Characteristics	Total	Arm A	Arm S	Pvalue
Number	423	300 (70.9)	123 (29.1)	NA
Sex
Male	320 (75.7)	223 (74.3)	97 (78.9)	0.324
Female	103 (24.3)	77 (25.7)	26 (21.1)
Age group
< 65	281 (66.4)	212 (70.7)	69 (56.1)	0.04
≥ 65	142 (33.6)	88 (29.3)	54 (43.9)
Histology (adenocarcinoma)
Well-moderate differentiated	97 (22.9)	61 (20.3)	36 (29.2)	0.145
Poorly differentiated	287 (67.8)	211 (70.3)	76 (61.8)
Signet-ring cell	24 (5.7)	18 (6.1)	6 (4.9)
Mucinous	15 (3.5)	10 (3.3)	5 (4.1)
Location of tumor
Proximal	147 (34.8)	95 (31.7)	52 (42.3)	0.07
Distal	276 (65.2)	205 (68.3)	71 (57.7)
Extent of LN dissection
< 15	202 (47.8)	136 (45.3)	66 (53.7)	0.12
≥ 15	221 (52.2)	164 (54.7)	57 (46.3)
Depth of invasion (T stage)
T1	9 (2.1)	7 (2.3)	2 (1.6)
T2	67 (15.8)	35 (11.7)	32 (26.0)
T3	204 (48.2)	165 (55.0)	39 (31.7)	0.529
T4a	89 (21.0)	52 (17.3)	37 (30.1)
T4b	54 (12.8)	41 (13.7)	13 (10.6)
No. of invaded LN (N stage)
N0 (0)	117 (27.7)	70 (23.3)	47 (38.2)	0.11
N1 (1-2)	126 (29.8)	100 (33.3)	26 (21.1)
N2 (3-6)	95 (22.5)	68 (22.7)	27 (22.0)
N3 (≥ 7)	85 (20.1)	62 (20.7)	23 (18.7)
AJCC stage (7.0 version)
IB	41 (9.7)	18 (6.0)	23 (18.7)	0.12
IIA	100 (23.6)	70 (23.3)	30 (24.4)
IIB	51 (12.1)	38 (12.7)	13 (10.6)
IIIA	56 (13.2)	48 (16.0)	8 (6.5)
IIIB	98 (23.2)	67 (22.3)	31 (25.2)
IIIC	77 (18.2)	59 (19.7)	18 (14.6)
Positive/harvested LN ratio
< 0.33	253 (59.8)	171 (57.0)	82 (66.7)	0.07
≥ 0.33	170 (40.2)	129 (43.0)	41 (33.3)
Vascular invasion
Positive	167 (39.5)	115 (38.3)	52 (42.3)	0.542
Negative	130 (30.7)	91 (30.3)	39 (31.7)
Unknown	126 (29.8)	94 (31.4)	32 (26.0)

LN: Lymph node; NA: Not available; AJCC: American Joint Committee on Cancer.

Table 2 Disease-free survival and overall survival of patients in Arm A received different chemotherapy regimens (n = 300)

	n	Cycles median (range)	Disease-free survival (mo) (95%CI)	Overall survival (mo) (95%CI)
Monotherapy	25	4 (2-15)
Doublet	164	6 (1-17)	38.4 (21.0-80.3)	63.2 (22.9-103.5)1
Monotherapy switched	38	8 (3-17)	NR1	NR1
No monotherapy switched	126	6 (1-12)	25.4 (18.7-32.1)	44.4 (28.3-60.5)
Triplet	111	6 (2-14)	45.8 (19.2-72.4)1	65.2 (43.5-87.0)1
Monotherapy switched	35	9 (5-14)	NR1	NR1
No monotherapy switched	76	6 (2-11)	24.9 (9.4-40.4)	56.2 (42.0-70.4)
Doublet and triplet	275	6 (1-17)	45.8 (23.8-67.8)	63.8 (41.4-86.2)
Monotherapy switched	73	8 (3-17)	NR1	NR1
No monotherapy switched	202	6 (1-12)	25.4 (18.3-32.5)	49.4 (35.7-63.1)

¹Statistically significance (P < 0.001). NR: Not reached.